
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International has demonstrated a positive sales trajectory within its Healthcare Systems & Technologies segment, with year-over-year sales increasing approximately 6% in 1Q25 and 2% in 2Q25, indicating robust demand for its medical products. The successful acquisition of Hillrom expanded Baxter's hospital-centric portfolio, providing a diversified range of essential medical equipment that supports revenue growth, while ongoing pricing initiatives are expected to contribute an estimated 100 basis points to sales growth in 2024 and 2025. As the market adjusts to new product launches and pricing strategies, Baxter is well-positioned to leverage its enhanced product offerings, suggesting a favorable outlook for sustained performance in the future.
Bears say
Baxter International's financial performance in 2Q25 exhibited significant shortfalls, as sales, margins, and earnings per share (EPS) failed to meet consensus expectations. Over the challenging period from 2021 to 2023, the company faced various operational missteps that resulted in inconsistent quarterly results and multiple negative guidance revisions. Compounding these issues, the company reported gross margins at 40.7% and operating margins at 15.1%, both of which fell notably below consensus estimates due to sales softness and manufacturing inefficiencies.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares